Arcturus Therapeutics 주식 (NASDAQ: ARCT)

에 대한 최신 뉴스 Arcturus Therapeutics (NASDAQ:ARCT) 주식

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Equities

News

Markets

ETFs

ARCT

ARKK

ARKQ

ARKW

BLDE

MKFG

NVDA

ROKU

2024년 6월 25일 화요일, 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 상당한 시장 변동성 속에서 엔비디아(NASDAQ:NVDA)와 로쿠(NASDAQ:ROKU)에서 상당한 거래를 했다. 이러한 거래는 아크의 다양한 ETF가 이행한 일련의 거래의 일부였다.

아크 인베스트는 주가 반등 속에 엔비디아 주식에서 $430만 매도, 로쿠 주식을 매수

$BTC

$ETH

ARKF

ARKG

ARKX

HOOD

TDOC

VERV

캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 수요일에 로빈후드 마켓(NASDAQ:HOOD) 및 줌 비디오 커뮤니케이션(NASDAQ:ZM)괴 관련하여 상당한 거래를 했다.
로빈후드 주식의 거래

아크 인베스트는 로빈후드 주식 150만 달러를 매도하며, 줌 주식 330만 달러 상당도 처분

EXAS

NTLA

VCYT

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:HOOD)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:

아크 인베스트가 게임스톱 관련 뉴스와 비트코인 변동성 속에서 로빈후드 주식 $7.6백만 매각

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc

ARCTIC STAR EXPL CORP by Arctic Star Exploration Corp.

Arctic Star Exploration Corp

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $60 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target

ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year
ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease
ARCT-032 IND for Phase 2 multiple ascending dose study to be submitted in the next 60 days
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:<a href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today is providing mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, an investigational inhaled mRNA therapeutic to treat cystic fibrosis (CF).

Biotech

General

Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs

On Tuesday, June 25, 2024, Cathie Wood-led Ark Invest made significant trades in NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), amidst considerable market volatility. These trades were part of a series of transactions carried out by Ark&#8217;s various ETFs.
The NVIDIA Trade
The firm&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) sold 33,834 NVIDIA shares on Tuesday. The transaction was valued at $4.3 million. On the day, Nvidia shares closed 6.8% higher at $126.09.
This move comes in the wake of a significant <a href="https://www.benzinga.com/top-stories/24/06/39490865/nvidia-rebounds-over-6-after-550b-market-cap-loss">market cap loss</a> for the tech giant, which saw a $550 billion drop since Thursday. Despite this, NVIDIA managed to rebound by over 6% on Tuesday, regaining its position as the third most valuable corporation, behind Microsoft Corporation and Apple Inc.
Concerns about NVIDIA&#8217;s influence on the S&amp;P 500 Index have been raised, with some analysts <a href="https://www.benzinga.com/trading-ideas/technicals/24/06/39482710/nvidia-stock-drops-over-12-in-3-trading-days-indicators-suggest-whats-next">warning of a potential broader market slump</a> if the company experiences a significant sell-off. Despite these concerns, NVIDIA&#8217;s fundamentals remain strong, with first-quarter 2024 earnings exceeding Wall Street's expectations, driven by strong performance in its data center and automotive segments.
The Roku Trade
ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) funds bought 96,465 Roku shares on Tuesday in a transaction valued at $5.3 million. Roku shares closed 0.35% higher at $54.64 in the regular session on Tuesday.
This move comes amidst a turbulent market for Roku, with its stock caught in a <a href="https://www.benzinga.com/general/entertainment/24/06/39422115/roku-stocks-wild-ride-bullish-analysts-bet-on-growth-despite-competitive-threats">fierce bull-bear debate</a> recently. Despite competitive threats, bullish investors are enthusiastic about Roku's revenue potential from several fronts.
The Netflix-rival recently unveiled Roku Exchange, an <a href="https://www.benzinga.com/markets/equities/24/06/39295418/whats-going-on-with-tv-streaming-platform-rokus-shares-on-wednesday">advertising technology solution</a> designed to bridge ad inventory with advertiser demand directly. This platform represents a significant advancement in streaming-first advertising technology, further solidifying Roku&#8217;s position in the market.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39448955/dogecoin-killer-shiba-inu-falters-here-is-what-these-key-indicators-reveal-about-its-short?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Killer&#8217; Shiba Inu Falters — Here Is What These Key Indicators Reveal About Its Short-Term Prosp</a>
Other Key Trades: 
<ul>
<li>Ark Invest&#8217;s ARKG fund sold a significant number of shares in Ginkgo Bioworks Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NASDAQ">DNA</a>). ARKG also bought shares in Arcturus Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) and 10X Genomics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>). </li>
<li>ARKK sold shares in Zoom Video Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) and bought shares in PagerDuty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>). ARKQ bought shares in Blade Air Mobility Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) and Markforged Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NASDAQ">MKFG</a>).</li>
</ul>
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39459711/stock-market-has-a-bad-breadth-problem-again-veteran-wall-street-investor-warns?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Stock Market Has A Bad Breadth Problem Again,&#8217; Veteran Wall Street Investor Warns</a>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival

Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Zoom Video Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>).
The Robinhood Trade
Ark Invest sold 64,706 shares of Robinhood, valued at approximately $1.53 million, through the Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>). This move comes after the company <a href="https://www.benzinga.com/markets/equities/24/06/39263031/cathie-wood-lead-ark-invest-dumps-7-6m-worth-of-robinhood-shares-amid-gamestop-buzz-bitcoin-chop">recently reduced its holdings</a> in Robinhood amid market fluctuations. The company&#8217;s shares are currently trading higher following the announcement of its May operating data.
Notably, the Robinhood trade took place on a day Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) saw some uptrend but the <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39303902/bitcoin-ethereum-dogecoin-fail-to-sustain-uptrend-after-feds-hawkish-guidance-analyst-fore">rally was not sustained</a> due to the Federal Reserve Bank&#8217;s hawkish guidance on interest rate cuts.
The Zoom trade
Ark Invest also sold 54,165 shares of Zoom, valued at approximately $3.3 million, through ARKW. This decision comes after the company <a href="https://www.benzinga.com/news/earnings/24/05/38926994/zoom-q1-earnings-revenue-beat-eps-beat-cash-flow-surges-continued-ai-integration-and-more">reported strong first-quarter earnings</a> last month, beating revenue and EPS estimates.
Other Key Trades: 
<ul>
<li>Ark Invest bought 21,260 shares of Markforged Holding Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NYSE">MKFG</a>) through the ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>). Ark Invest also bought 8,776 shares of Markforged through the ARK Space Exploration &amp; Innovation ETF (BATS: ARKX).</li>
<li>Ark Invest bought 15,383 shares of PagerDuty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) through the ARK Innovation ETF (NYSE: ARKK). Ark Invest bought 39,589 shares of Arcturus Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) through the ARK Genomic Revolution ETF (BATS: ARKG). </li>
<li>Ark Invest sold 229,654 shares of Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) through the ARKW ETF. Ark Invest sold 125,257 shares of Verve Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) through the ARKK ETF. The firm also sold 24,866 shares of Verve through the ARKG ETF.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39278216/donald-trump-opens-21-point-lead-in-2024-presidential-race-according-to-crypto-bettors?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Donald Trump Opens 21-Point Lead In 2024 Presidential Race, According To Crypto Bettors</a>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio.
The HOOD Trade: Ark Invest&#8217;s decision to trim its position in Robinhood was executed through three of its ETFs. The ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) sold 31,827 shares, while the ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and the ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) offloaded 215,675 and 76,299 shares respectively. Based on Robinhood&#8217;s closing price of $23.42 on Monday, the total value of the shares sold is approximately $7.6 million. 
The volatility in Robinhood shares comes amid a <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock">revival of the meme stock saga</a>, recently Robinhood CEO Vlad Tenev announced that the company was prepared to handle any traffic influx resulting from a scheduled live stream from Roaring Kitty, also known as Keith Gill, who is famous for his investments in GameStop Corporation. The company also recently announced a <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">$1 billion buyback</a>, which contributed to the stock&#8217;s upward trend.
Notably, the trade was executed in the background of a <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-">choppy cryptocurrency market</a> when major coins like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) traded in the red.
Other Key Trades: 
<ul>
<li>Exact Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): Sold shares via ARKG and shares via ARKK.</li>
<li>Arcturus Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): Purchased shares via ARKG. </li>
<li>Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): Sold shares via ARKG. </li>
<li>Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): Bought shares via ARKG and shares via ARKK. </li>
<li>Verve Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): Sold shares via ARKG and shares via ARKK. Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): Bought 5,804 shares via ARKG and shares via ARKK.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Investor Naval Ravikant Threatens To Sell All Tesla Holdings If CEO Musk&#8217;s Pay Plan Is Rejected But Says He&#8217;ll Buy More If Approved</a>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness

Friday, Arcturus Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with cystic fibrosis for ARCT-032, an inhaled investigational mRNA therapeutic, at the European Cystic Fibrosis Conference.
ARCT-032 administration was generally safe and well tolerated, with no serious or severe adverse events in healthy volunteers and the first four dosed <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/b39228726/arcturus-therapeutics-presents-new-clinical-data-at-47th-annual-european-cystic-fibrosis-conferenc" rel="noreferrer noopener">participants with cystic fibrosis</a>.
The Phase 1b trial showed improvements in FEV1 (Forced Expiratory Volume in 1 second) in the four adults with cystic fibrosis after two inhaled administrations.
The absolute change in percent predicted FEV1 averaged +4.0% on Day 8 (5 days after 2nd&nbsp;dose). The relative change in FEV1 averaged +5.8% on Day 8.
The observed increases in FEV1 are encouraging and consistent with the previously reported data in the CF ferret model that demonstrated markedly improved mucociliary clearance (MCC) after a single dose of ARCT-032.
Of the four participants in Phase 1b to date, one had 2 Class I mutations, and the other three had F508del mutations and were being treated with Vertex Pharmaceuticals&nbsp;Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) Trikafta.
No bronchospasm or febrile reactions were observed. Dose-related, mild-to-moderate febrile reactions occurred in some healthy volunteers.
William Blair notes that despite important limitations such as the small patient sample size, differences in baseline characteristics, and significant within-patient variability, the overall data is encouraging in two key areas:
<ul>
<li>Firstly, in light of Vertex&#8217;s recent studies on its next-generation Vanza triple treatment, which did not show superior FEV1 improvement compared to Trikafta, William Blair is intrigued by the potential additional benefits observed in three patients with amendable mutations.</li>
<li>Second, the 4% absolute benefit and over 5.8% relative improvement seen in Class I null mutation patients—who currently lack treatment options—are comparable to the early Phase I results of ivacaftor during its CFTR modulator development.</li>
</ul>
The analyst says the results are also promising compared to a ferret model of cystic fibrosis, which accurately mimics key aspects of the disease, such as mucus buildup.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/ARCT/analyst-ratings" rel="noreferrer noopener">Outperform rating on Arcturus</a>, saying it is a leader in self-amplifying mRNA vaccine technology and advancing an mRNA therapeutics platform with a differentiated lipid nanoparticle delivery system.
Price Action: ARCT shares are down 27.9% at $30.72 at last check Friday.
Photo by Minerva Studio via Shutterstock

Analyst Color

Health Care

Movers

Trading Ideas

VRTX

Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst

WIIM

Arcturus Therapeutics shares are trading lower. The company announced that it presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032 at the 47th European Cystic Fibrosis Conference.

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 87.9% to $1.1 during Friday's regular session. The company's market cap stands at $7.0 million. </li>
<li>Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) stock moved upwards by 41.22% to $0.33. The market value of their outstanding shares is at $90.3 million. </li>
<li>American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) shares rose 29.41% to $2.2. The market value of their outstanding shares is at $22.4 million. </li>
<li>Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) shares rose 29.33% to $2.8. The market value of their outstanding shares is at $72.6 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock increased by 22.12% to $1.38. The market value of their outstanding shares is at $60.8 million. </li>
<li>Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) stock rose 21.07% to $4.71. The market value of their outstanding shares is at $2.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) stock declined by 63.1% to $4.16 during Friday's regular session. The company's market cap stands at $149.5 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 32.02% to $2.82. The market value of their outstanding shares is at $1.6 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 22.64% to $0.66. The company's market cap stands at $99.9 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock declined by 20.08% to $0.78. The company's market cap stands at $33.6 million. </li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares fell 18.24% to $34.83. The company's market cap stands at $938.0 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock declined by 17.7% to $0.09. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANEB

AONC

ASXC

BMEA

GERN

INAB

MCRB

NDRA

SCNI

VERO

12 Health Care Stocks Moving In Friday's Intraday Session

ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cystic fibrosis (CF)
Phase 1b interim data includes a CF participant with Class 1 mutations and three participants with F508del mutations being treated with Trikafta&#xAE;
Early trend of improved lung function with an average absolute response of +4.0% (ranging up to +9%) and relative change of +5.8% FEV1 on Day 8, after two doses of ARCT-032
Clinical data is consistent with pre-clinical CF ferret model data

Arcturus Therapeutics Presents Phase 1 Results For ARCT-032 At European Cystic Fibrosis Conference

On Tuesday,&nbsp;Arcturus Therapeutics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) announced that it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in cystic fibrosis (CF) for ARCT-032 at the European&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b39034584/arcturus-therapeutics-announces-positive-development-for-cystic-fibrosis-program" rel="noreferrer noopener">Cystic Fibrosis Conference</a>.
&#8220;We were pleased to observe ARCT-032 treatments for the first four patients were generally safe and well tolerated with no serious adverse events,&#8221; said Joseph Payne, President &amp; CEO of Arcturus Therapeutics. &#8220;Furthermore, we observed an encouraging trend towards lung function improvements in the first four CF participants after only two inhaled administrations.&#8221;
&#8220;The absolute change in percent predicted FEV1 (Forced Expiratory Volume in 1 second) in the first four CF participants was observed to be an average of 4.0% at day 8,&#8221; said Dr. Juergen Froehlich, Chief Medical Officer of Arcturus Therapeutics.
William Blair&nbsp;notes that the results are encouraging, although several key questions remain&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36221670/arcturus-therapeutics-lung-disease-candidate-triggers-bullish-rating-analyst-sees-o" rel="noreferrer noopener">ahead of the presentation</a>.
William Blair&#8217;s analyst notes it is crucial to determine if the patients were using&nbsp;Vertex Pharmaceuticals Incorporated&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) Trikafta or if they had a genetic deletion, making them ineligible for CFTR modulator therapy.&nbsp;
A 4% improvement over Trikafta would be significant,&nbsp;especially&nbsp;since Vertex&#8217;s second-generation Vanza triple did not outperform the current Trikafta treatment. Thus, an additional 4% improvement could be impactful.
As William Blair looks forward to additional detail at the conference presentation on June 7 and the planned company update on July 1, the preliminary results are encouraging if able to show an improvement on top of the standard of care or in those patients who are ineligible for current CFTR modulators.&nbsp;
Arcturus&#8217; current share value is primarily driven by Kostaive commercial expectations, CSL profit sharing from respiratory vaccine programs, and the company&#8217;s cash position, with minimal value attributed to the therapeutic pipeline.
The analyst reaffirms the Outperform rating.
Price Action:&nbsp;ARCT shares are up 21.90% at $37.07 at the last check on Tuesday.

Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic

Shares of Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell sharply during Tuesday's session after the company announced the pricing of a $12 million public offering.
Applied DNA Sciences shares tumbled 67.5% to $0.6468 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares climbed 207% to $0.6579 after jumping around 13% on Friday.</li>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) jumped 110% to $46.20 after the company announced topline results from ASPEN Phase 3 study met its primary endpoint.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares gained 91.5% to $0.3411 after the company on Friday announced its SUNation subsidiary signed a 1.95-megawatt project.</li>
<li>Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) shares gained 74.6% to $38.10 after the company&#8217;s board recommended the acceptance of Asahi Kasei&#8217;s tender offer.</li>
<li>Visionary Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) rose 68% to $0.3350. Visionary Holdings said that the company has successfully transformed into a high-innovation and high growth company.</li>
<li>Oblong, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) surged 57% to $0.2841.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) rose 45.2% to $20.47.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) jumped 37% to $2.1801 after the company announced results from its ovarian caner study with UPMC Magee-Womens Hospital.</li>
<li>Trinity Place Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NASDAQ">TPHS</a>) rose 35% to $0.1837.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 31% to $0.4359.</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) rose 30% to $1.1000.</li>
<li>Kuke Music Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KUKE#NYSE">KUKE</a>) gained 24.2% to $3.2781. Kuke Music signed a non-binding term sheet with Naxos One Holding.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) rose 22% to $38.29 after the company announced it agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier&#8217;s vorasidenib to Royalty Pharma.</li>
<li>Arcturus Therapeutics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) gained 21% to $36.63 after the company announced it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 19.3% to $0.1205 after dipping over 10% on Friday.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares gained 16.7% to $0.2240 after gaining around 5% on Friday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) gained 14.4% to $0.3411 after the company announced it has completed its at-the-market equity offering program, which was previously announced.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) climbed 13.7% to $31.20 after the company announced that its Phase 3 GRACE trial met its primary endpoint.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) rose 13% to $13.93.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 11.7% to $8.68 after jumping over 16% on Friday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) rose 10.9% to $1.0201.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) gained 10.1% to $11.78.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) rose 10.1% to $11.18.</li>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) gained 6.9% to $631.00.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Marpai, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAI#NASDAQ">MRAI</a>) shares fell 54.7% to $0.6468 after the company announced its intention to withdraw from the Nasdaq hearings process.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 47.4% to $0.5170 after surging 428% on Friday.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) fell 41% to $8.00.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) dipped 27.7% to $0.1390 after the company announced that it entered into definitive agreement for the immediate exercise of $2.2 million of certain outstanding Series A-2 warrants.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares fell 24.4% to $1.77 after jumping 56% on Friday. OneMedNet, last week, highlighted a &#8216;five-fold expansion&#8217; of its iRWD network and platform.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) fell 22.8% to $2.61.</li>
<li>Akanda Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares fell 18.5% to $3.35 following a 72% surge on Friday. The international medical cannabis company implemented a 1-for-40 reverse stock split on its ordinary shares effective May 23, 2024, according to a recent exchange filing.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) fell 17.8% to $8.25.</li>
<li>G1 Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) declined 17.6% to $3.37.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) fell 15.6% to $1.8399.</li>
<li>HilleVax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) fell 13.6% to $11.14.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) dipped 13.3% to $82.08.</li>
<li>Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) declined 12.6% to $9.38.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) fell 12.4% to $13.56.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) declined 12.3% to $3.52. NWTN received expected notification from the Nasdaq related to delayed annual report on Form 20-F.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) dipped 11% to $36.29 after the Illinois Senate approved a 2025 budget that includes a sports betting tax hike.</li>
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) fell 9.5% to $54.28 as the company revealed interim results for bispecific antibody petosemtamab with pembrolizumab at 2024 American Society of Clinical Oncology Annual Meeting.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) dipped 9.2% to $151.28.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) declined 9.1% to $112.24 after RBC Capital downgraded the stock from Outperform to Sector Perform.</li>
<li>Minim, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares fell 8.6% to $3.91 after gaining 33% on Friday.</li>
<li>Applied UV, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUVI#NASDAQ">AUVI</a>) shares fell 8.5% to $0.2879. Applied UV shares fell around 34% on Friday after the company reportedly filed for Chapter 11 bankruptcy.</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) declined 7% to $51.36.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) declined 6% to $67.75 after the company&#8217;s Shopee was reportedly accused of suspected anti-competition breaches in Indonesia.</li>
<li>Hello Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) fell 5.8% to $5.20 following first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39038936/1-5m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying">$1.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Intraday Update

AGIO

AKAN

APDN

AUVI

CALT

CELH

CORT

CRKN

DKNG

EDBL

FWRD

GTHX

HLVX

HUBS

INSM

KUKE

LOAR

LUCY

MINM

MOMO

MRAI

MRNA

MRUS

NCPL

NUKK

NVAX

NWTN

OBLG

OKLO

ONMD

OPTT

PEGY

POAI

RYDE

SINT

SMMT

SMXT

SPCE

SRPT

STSS

TPHS

XCUR

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Tuesday.
Shares of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose during Tuesday's session on reports Elon Musk&#8217;s xAI plans to build a supercomputer that will power its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39037833/magnificent-7-becomes-the-magnificent-one-wall-street-guru-hails-single-tech-stock-">Grok AI chatbot</a>.
The company, last week, reported better-than-expected financial results for its first quarter and issued strong <a href="https://www.benzinga.com/24/05/38997534/nvidias-market-dominance-seems-bubbly-says-renowned-wall-street-investor-rob-arnott">guidance for the second quarter.</a>
NVIDIA shares gained 4.4% to $1,110.87 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) shares climbed 110% to $46.20 after the company announced topline results from ASPEN Phase 3 study met its primary endpoint.</li>
<li>Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) shares rose 74.6% to $38.10 after the company&#8217;s board recommended the acceptance of Asahi Kasei&#8217;s tender offer.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares jumped 45.2% to $20.47.</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares surged 30% to $1.1000.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) jumped 22% to $38.29 after the company announced it agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier&#8217;s vorasidenib to Royalty Pharma.</li>
<li>Arcturus Therapeutics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares rose 21% to $36.63 after the company announced it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) climbed 14.4% to $0.3411 after the company announced it has completed its at-the-market equity offering program, which was previously announced.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares rose 13.7% to $31.20 after the company announced that its Phase 3 GRACE trial met its primary endpoint.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) jumped 13% to $13.93.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) rose 11.7% to $8.68 after jumping over 16% on Friday.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) climbed 10.1% to $11.78.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) gained 10.1% to $11.18.</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares climbed 8.8% to $194.12. JMP Securities analyst Andrew Boone upgraded Duolingo from Market Perform to Market Outperform and announced a price target of $260.</li>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) rose 6.9% to $631.00.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) gained 6.4% to $122.07.</li>
<li>Pan American Silver Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NASDAQ">PAAS</a>) gained 5.2% to $22.12.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) rose 4.8% to $23.59.</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) shares rose 4.7% to $16.75 after Mizuho upgraded the stock from Neutral to Buy.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39037640/top-5-real-estate-stocks-that-could-lead-to-your-biggest-gains-this-month">Top 5 Real Estate Stocks That Could Lead To Your Biggest Gains This Month</a>

DUOL

MNSO

NCLH

PAAS

Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

CORT: 41% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39037043">Corcept Therapeutics shares are trading higher after the company announced that its Phase 3 GRACE trial met its primary endpoint.</a>
ARCT: 21% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39036060">Arcutus Therapeutics Holdings shares are trading higher after the company announced it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032.</a>
INSM: 189% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39033110">Reported Monday, Insmed To Discuss Topline Results From Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis</a>

Market-Moving News for May 28th

Arcutus Therapeutics Holdings shares are trading higher after the company announced it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032.

<h1>Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program</h1>
Business Wire
Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024
First four CF patients demonstrated an average improvement of&nbsp;4%&nbsp;FEV1 after two administrations
Arcturus Therapeutics Holdings Inc. ((the &quot;Company&quot;, &quot;Arcturus&quot;, NASDAQ:<a href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic to treat CF, at the 47th&nbsp;European Cystic Fibrosis Conference on June 7, 2024.

Arcturus Therapeutics Reports Phase 1b Data for Cystic Fibrosis Treatment

ACHL

Achilles Therapeutics And Arcturus Therapeutics Announce Research Collaboration To Explore mRNA Cancer Vaccines

<ul>
<li>Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan.&nbsp;</li>
<li>These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.</li>
</ul>
KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ --&nbsp;Global biotechnology leader&nbsp;CSL ((ASX:CSL, OTC:<a href="https://www.benzinga.com/stock/CSLLY#OTC">CSLLY</a>) and Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.

CSLLY

CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and lowers the price target from $87 to $86.

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $86

Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the <a href="https://www.benzinga.com/markets/penny-stocks/24/04/38491524/mrna-is-promising-a-breakthrough-in-fighting-cancer">mRNA technology, </a>which is the core of new-age vaccines.
What Happened: Social-media personality and prominent YouTuber Ed Krassenstein lauded the mRNA technology in a post on X, stating that it will &#8220;save millions of American lives in the future, if Republicans don't get in the way.&#8221;
The view was seconded by Musk, who is very active on the platform he owns. Replying to Krassenstein&#8217;s post, he said, &#8220;Synthetic mRNA is basically digital medicine with incredible potential.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Synthetic mRNA is basically digital medicine with incredible potential
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1788263974871437743?ref_src=twsrc%5Etfw">May 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption"> See Also: <a href="https://www.benzinga.com/money/best-biotech-stocks">Best Biotech Stocks Right Now</a> The Technology: So, what is this mRNA tech that Musk has a lot of confidence in? mRNA, with the &#8220;m&#8221; there standing for messenger, is a molecule that contains the instructions that direct the cells to make a protein using its natural machinery. When this synthetically developed mRNA reaches the cell in a protective bubble called a lipid nanoparticle, the cells read the set of instructions and begin making proteins that are found in the pathogen. Our body&#8217;s immune system sees these as invaders and produces antibodies and T-cells, and in the process trains the immune system to defend against potential future attacks. The vaccines developed against COVID-19 by most companies in the aftermath of the pandemic used the technology. Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)-BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), and Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), which have FDA-approved vaccines against COVID-19, relied on the mRNA technology for developing their respective. Republicans Shun It: GOP voters and lawmakers, especially those who are more right-leaning, have been against the COVID-19 vaccines. In fact, the anti-vaxx movement, backed by Republicans, has taken on a political color. A Politico/Morning Consult poll conducted in late 2023 showed that 51% of the Republicans cared more about the health risk posed by the vaccine compared to the 49% of the respondents, who focused on the healthy benefits. In comparison, among the overall respondents, the split was 38% to 62%. As is the case with any new technology, skepticism abounds until science can prove that its potential benefits outweigh the risks. Safety for that matter was an issue with the COVID-19 vaccine developed by AstraZeneca plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) along with Oxford University using the traditional vaccine technology. mRNA Bets: The global mRNA therapeutics market size, estimated at $11.75 billion in 2023, is expected to grow at a CAGR of 17.05% from 2024 to 2030, according to estimates by Grand View Research. If mRNA is going to be the technology of the future, as Musk and others claim, here are a few stocks that investors can consider adding to their portfolios. 1. Moderna (for skin cancer, flu, respiratory syncytial virus, and HIV, etc) 2. Arcturus Therapeutics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) (for Ornithine transcarbamylase, cystic fibrosis, etc) 3. BioNTech (for cancers) 4. CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) (for flu, COVID-19, cancers) 5. GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) (for infectious diseases and cancers) The SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) ended Wednesday&#8217;s session down 1.46% to $89.11, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data.</a></figcaption></figure>
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38189886/vaccine-player-vaxcyte-has-advantage-over-pfizer-mercks-pneumococcal-shots-analyst-">Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck&#8217;s Pneumococcal Shots &#8211; Analyst Says</a>
Photo via Shutterstock

Tech

BNTX

CVAC

GOVX

Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'

Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.19) by 15.97 percent. This is a 153.48 percent decrease over earnings of $1.87 per share from the same period last year. The company reported quarterly sales of $38.01 million which beat the analyst consensus estimate of $17.54 million by 116.72 percent. This is a 52.65 percent decrease over sales of $80.28 million the same period last year.

Earnings

Earnings Beats

Arcturus Therapeutics Q1 EPS $(1.00) Beats $(1.19) Estimate, Sales $38.01M Beat $17.54M Estimate

Arcturus: A Hidden Gem In The Biotech Sector

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN – Research Report), ...

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Arcturus Therapeutics (ARCT) and Blueprint Medicines (BPMC)

Arcturus Therapeutics (ARCT) has shared an update. Arcturus Therapeutics Holdings Inc. stockholders convened for their annual meeting, endorsing a ...

Arcturus Therapeutics Endorses Plan Amendment and Re-elects Board

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report), BioN...

Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), BioNTech SE (BNTX) and Tempest Therapeutics (TPST)

Arcturus Therapeutics (ARCT) has shared an announcement. Arcturus Therapeutics Holdings Inc. has appointed Dr. Moncef Slaoui to its Board of Direct...

Arcturus Therapeutics Enhances Board with Industry Expert Dr. Slaoui

Arcturus to file IND for phase 2 study for cystic fibrosis candidate

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of $60.00. E...

Buy Rating Affirmed: Promising Developments in Arcturus Therapeutics' mRNA Treatments for Rare Diseases

Wells Fargo analyst Yanan Zhu has maintained their bullish stance on ARCT stock, giving a Buy rating today. Yanan Zhu has given his Buy rating due ...

Buy Rating for Arcturus Therapeutics: Advancing Clinical Programs and Strengthening Safety Profile

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a pri...

Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 7/3/2024, According to Top Analysts

APLD

BMRN

BPMC

TPST

Press Releases

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Small Cap

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Arcturus Therapeutics

뉴스

에 대한 최신 뉴스 Arcturus Therapeutics (NASDAQ:ARCT) 주식

수요일, 6월 26, 2024

목요일, 6월 13, 2024

화요일, 6월 11, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌